Insulin aspart, recombinant Subcutaneous and Panitumumab
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Panitumumab and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Panitumumab Intravenous
- Insulin aspart, recombinant Subcutaneous-Panixine
- Insulin aspart, recombinant Subcutaneous-Panixine DisperDose
- Insulin aspart, recombinant Subcutaneous-Panlor
- Insulin aspart, recombinant Subcutaneous-Panlor Tablet
- Insulin aspart, recombinant Subcutaneous-Panlor Tablets
- Panitumumab-Insulin degludec
- Panitumumab-Insulin Degludec (U-100) Prefilled Pens
- Panitumumab-Insulin Degludec (U-100) Vials
- Panitumumab-Insulin Degludec (U-200) Prefilled Pens
- Panitumumab-Insulin degludec and liraglutide
- Panitumumab-Insulin degludec and liraglutide Subcutaneous